Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 46 results:
Συντάκτης Τίτλος [ Τύπος(Desc)] Έτος
Φίλτρα: Συντάκτης is Goulas, Antonis  [Clear All Filters]
Journal Article
Papaefthymiou, A., Potamianos S., Goulas A., Doulberis M., Kountouras J., & Polyzos S. A. (2021).  Inflammatory Bowel Disease-associated Fatty Liver Disease: the Potential Effect of Biologic Agents.. J Crohns Colitis.
Fidani, L., Goulas A., Mirtsou V., Petersen R. C., Tangalos E., Crook R., et al. (2002).  Interleukin-1A polymorphism is not associated with late onset Alzheimer's disease.. Neurosci Lett. 323(1), 81-3.
Chatzidakis, K., Goulas A., Athanassiadou-Piperopoulou F., Fidani L., Koliouskas D., & Mirtsou V. (2006).  Methylenetetrahydrofolate reductase C677T polymorphism: association with risk for childhood acute lymphoblastic leukemia and response during the initial phase of chemotherapy in greek patients.. Pediatr Blood Cancer. 47(2), 147-51.
Fidani, L., Compton D., Hardy J., Petersen R. C., Tangalos E., Mirtsou V., et al. (2002).  No association between the lipoprotein lipase S447X polymorphism and Alzheimer's disease.. Neurosci Lett. 322(3), 192-4.
Vachliotis, I. D., Anastasilakis A. D., Goulas A., Goulis D. G., & Polyzos S. A. (2022).  Nonalcoholic fatty liver disease and osteoporosis: A potential association with therapeutic implications.. Diabetes Obes Metab. 24(9), 1702-1720.
Vachliotis, I., Goulas A., Papaioannidou P., & Polyzos S. A. (2021).  Nonalcoholic fatty liver disease: lifestyle and quality of life.. Hormones (Athens).
Constantinos, Z., Eleni P., Goulas A., & Iakovidou-Kritsi Z. (2015).  Olanzapine: evaluation of the in vivo cytogenetic effect.. Hum Psychopharmacol. 30(3), 189-92.
Deliligka, A., Raikos N., Chatzinikolaou F., Venizelos I., Chatzopoulos K., & Goulas A. (2016).  Potential use of pericardial cTnI, Mg and Ca in the forensic investigation of seawater drowning in Greece: An initial assessment.. Leg Med (Tokyo). 23, 30-33.
Kaprinis, S., Parlapani E., Raikos N., Goulas A., & Karpouza V. (2014).  Psychotic episode associated with sertraline and drug-related delirium: a case report.. J Clin Psychopharmacol. 34(4), 527-9.
Orfanidou, M., Ntenti C., Evripidou K., Mataftsi A., Goulas A., & Polyzos S. A. (2023).  Retinal Vascular Lesions in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.. J Pers Med. 13(7), 
Kopelli, E., Samara M., Siargkas A., Goulas A., Papazisis G., & Chourdakis M. (2020).  The role of cannabidiol oil in schizophrenia treatment. a systematic review and meta-analysis.. Psychiatry Res. 291, 113246.
Tsiampali, C., Papaioannidou P., Goulas A., & Polyzos S. A. (2023).  The role of glucagon-like peptide-1 receptor agonists in nonalcoholic fatty liver disease. Expert Review of Clinical Pharmacology. 1 - 10.
Tsiampali, C., Papaioannidou P., Goulas A., & Polyzos S. A. (2023).  The role of glucagon-like peptide-1 receptor agonists in nonalcoholic fatty liver disease.. Expert Rev Clin Pharmacol. 1-10.
Molyva, D., Kalokasidis K., Poulios C., Dedi H., Karkavelas G., Mirtsou V., et al. (2014).  Rupatadine effectively prevents the histamine-induced up regulation of histamine H1R and bradykinin B2R receptor gene expression in the rat paw.. Pharmacol Rep. 66(6), 952-5.
Polyzos, S. A., Kountouras J., Goulas A., & Duntas L. (2020).  Selenium and selenoprotein P in nonalcoholic fatty liver disease.. Hormones (Athens). 19(1), 61-72.
Makri, E. S., Goulas A., & Polyzos S. A. (2021).  Sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease.. Eur J Pharmacol. 907, 174272.
Karampatakis, V., Papanikolaou T., Giannousis M., Goulas A., Mandraveli K., Kilmpasani M., et al. (2009).  Stability and antibacterial potency of ceftazidime and vancomycin eyedrops reconstituted in BSS against Pseudomonas aeruginosa and Staphylococcus aureus.. Acta Ophthalmol. 87(5), 555-8.
Timonen, J. M., Nieminen R. M., Sareila O., Goulas A., Moilanen L. J., Haukka M., et al. (2011).  Synthesis and anti-inflammatory effects of a series of novel 7-hydroxycoumarin derivatives.. Eur J Med Chem. 46(9), 3845-50.
Polyzos, S. A., Goulas A., & Papaioannidou P. (2023).  Tirzepatide for Diabetes and Obesity: A New Window to the Treatment of Non-alcoholic Steatohepatitis.. Curr Med Chem.
Polyzos, S. A., Goulas A., & Papaioannidou P. (2023).  Tirzepatide for Diabetes and Obesity: A New Window to the Treatment of Non-alcoholic Steatohepatitis. Current Medicinal Chemistry. 30,
Polyzos, S. A., & Goulas A. (2020).  Treatment of nonalcoholic fatty liver disease with an anti-osteoporotic medication: A hypothesis on drug repurposing.. Med Hypotheses. 110379.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές